ArticleJournal of neurology2024

The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis.

Isabel Monteiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.